Drugs / Pyruvate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05695027 | Mar 2023 → Aug 2027 expected | open-angle glaucoma | Columbia University | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00604331 Comparator | Aug 2008 → Jul 2009 | acute myocardial infarction, cardiogenic shock, heart failure | Herzzentrum Goettingen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05695027 ↗ |
| Route | Oral | “combination of oral nicotinamide and pyruvate” NCT05695027 ↗ |